Additive Interaction Between the Renin-Angiotensin System and Lipid Metabolism for Cancer in Type 2 Diabetes
Open Access
- 28 April 2009
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 58 (7), 1518-1525
- https://doi.org/10.2337/db09-0105
Abstract
OBJECTIVE: Clinical and experimental studies suggest cross-talk between lipid metabolism and the renin-angiotensin system (RAS) in atherogenesis. The aim of this study was to explore interactions between these two systems in mediating cancer risk in type 2 diabetes. RESEARCH DESIGN AND METHODS: A prospective cohort of 4,160 Chinese patients with type 2 diabetes, free of cancer at enrollment, were analyzed using Cox models. Interaction of RAS inhibitors (angiotensin I–converting enzyme inhibitors or angiotensin II receptor blockers) and statins was estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S). RERI > 0, AP > 0, or S > 1 indicates additive interaction between the two classes of drugs. Molecular mechanisms underlying these interactions were explored using a uninephrectomy (UNX) rat model with renal carcinogenesis. RESULTS: During 21,992 person-years of follow-up, 190 patients developed cancer. Use of RAS inhibitors and statins in isolation or combination during follow-up was associated with reduced risk of cancer after adjustment for covariates. The multivariable RERI and AP for the additive interaction between these drug classes for cancer were significant (0.53 [95% CI 0.20–0.87] and 2.65 [0.38–4.91], respectively). In the UNX rat model, inhibition of the RAS prevented renal cell carcinoma by normalizing hydroxymethylglutaryl-CoA reductase (HMGCR) expression and the insulin-like growth factor-1 (IGF-1) signaling pathway. CONCLUSIONS: Combined use of RAS inhibitors and statins may act synergistically to reduce cancer risk, possibly via HMGCR and IGF-1 signaling pathways in high-risk conditions such as type 2 diabetes.Keywords
This publication has 47 references indexed in Scilit:
- Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information systemBMC Endocrine Disorders, 2008
- Insulin and insulin-like growth factor signalling in neoplasiaNature Reviews Cancer, 2008
- Fat redistribution and adipocyte transformation in uninephrectomized ratsKidney International, 2008
- Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptorBiochemical and Biophysical Research Communications, 2008
- Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitusCMAJ : Canadian Medical Association Journal, 2008
- Insulin-like growth factor-1 coordinately induces the expression of fatty acid and cholesterol biosynthetic genes in murine C2C12 myoblastsBMC Genomics, 2008
- Diabetes mellitus and breast cancer: a retrospective population-based cohort studyBreast Cancer Research and Treatment, 2006
- Cross-talk between dyslipidemia and renin–angiotensin system and the role of LOX-1 and MAPK in atherogenesis: Studies with the combined use of rosuvastatin and candesartanAtherosclerosis, 2006
- Calculating measures of biological interactionEuropean Journal of Epidemiology, 2005
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004